drugset / Trial / NCT03790085

Summary

This study aims to screen and validate multi-scale bio-markers for early diagnosis and medication monitoring for early schizophrenia, including the genetic, neurobiochemistry, neuroimaging and eletrophysiological measures. Based on the validated bio-markers, the present study further tries to build several prediction models for early differential diagnosis of schizophrenia from healthy controls and other mental diseases (such as the major depression and anxiety disorders), biological sub-typing and diagnosis of the schizophrenia sub-types, and early prediction of the medication effects.

Timeline

Start
2018-09-01
Primary completion
2020-06-30
Completion
2020-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified 30 mg Oral
Subject Olanzapine Small molecule 20 mg
Subject Risperidone Other / unclassified 6 mg Oral